Press Releases

CE marking of bioMérieux serology tests for SARS-CoV-2 on VIDAS®

bioMérieux, a world leader in the field of in vitro diagnostics, today announced the CE marking of VIDAS® anti-SARS-CoV-2 serology tests to detect antibodies in people who have been exposed to SARS-Co...

Information concerning 2019 dividend and the bioMérieux General Shareholders’ Meeting

The Board of Directors of bioMérieux met today and decided to hold the annual General Shareholders’ Meeting behind closed doors at the bioMérieux registered office on June 30, 2020. During this meetin...

bioMérieux serology tests for SARS-CoV-2 on VIDAS® undergo validation preceding imminent launch

bioMérieux, a world leader in the field of in vitro diagnostics, today announced performance validation and the upcoming launch of VIDAS® anti-SARS-CoV-2 serology tests to detect antibodies in people ...

Business & Solutions

Validation de la performance des tests sérologiques VIDAS® de bioMérieux pour le SARS-CoV-2 avant un lancement imminent

bioMérieux, acteur majeur dans le domaine du diagnostic in vitro, annonce la validation de la performance et le lancement prochain des tests sérologiques VIDAS® anti-SARS-CoV-2 pour la détection des a...

BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 obtains FDA Emergency Use Authorization

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in syndromic infectious disease testing, has received Emergency Us...

First-Quarter 2020 Business Review

bioMérieux fully mobilized against COVID-19 epidemic Organic growth of more than 20% at constant exchange rates and scope of consolidation over the first quarter: €769 million in sales Up 21.5% as rep...

bioMérieux’s Annual General Meeting postponed

Due to the unprecedented circumstances linked to the COVID-19 pandemic, the Board of Directors of bioMérieux, which met today, has decided to postpone the Annual General Meeting initially scheduled on...

bioMérieux receives Emergency Use Authorization for BIOFIRE® COVID-19 test

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that its subsidiary, BioFire Defense, has received Emergency Use Authorization by the U.S. Food and Drug Administration...

First of 3 diagnostic tests for SARS-CoV-2 coronavirus available from bioMérieux

bioMérieux, a world leader in the field of in vitro diagnostics, is announcing the forthcoming launch of 3 different tests to address the COVID-19 epidemic and to meet the different needs of physician...

2019 Financial Results

€2,675 million in sales for full-year 2019, representing a reported increase of 10.5% and organic growth of 7.2% Strong sales momentum in the fourth quarter, with organic growth of 8.3% driven by sale...

Résultats annuels au 31 décembre 2019

Chiffre d’affaires 2019 de 2 675 millions d’euros, en hausse de 10,5 % à données publiées, soit une croissance organique de 7,2 % Solide dynamique commerciale au 4e trimestre, avec une croissance orga...

bioMérieux submits enhanced BIOFIRE® BCID2 Panel for FDA clearance

bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology affiliate, has submitted to the Food and Drug Administration for 510(k) clear...

bioMérieux and the Fleming Fund: working together to strengthen diagnostic capacity and tackle antimicrobial resistance in low- and middle-income countries

London (UK), Marcy l’Étoile (France) – December 18, 2019 – bioMérieux, a world leader in in vitro diagnostics which develops and manufactures testing solutions (systems, reagents, software, services) ...

Third-Quarter 2019 Business Review

Organic growth of 6.8% at constant exchange rates and scope of consolidation over the first nine months of the year: €1,928 million in sales Up 10.3% as reported Acceleration of organic growth in sale...

First-Half 2019 Results

bioMérieux – First-Half 2019 Results Organic sales growth of 5.5% for first-half 2019: €1,275 million in sales Up 9.1% as reported As expected, growth accelerated in the second quarter, up to 7.4% at ...